ISPOR 2025

Alignment Between CDA Recommendations and pCPA Negotiation Outcomes: Exploring Factors Influencing Reimbursement Success

Join HTA-Hive at ISPOR 2025 as CEO Mackenzie Mills presents new research on the disconnect between Canada’s HTA recommendations and pCPA negotiation outcomes.

A Retrospective Analysis of the Italian Medicines Agency's Evaluation of Real World Evidence in Innovativeness Assessments

Presented at ISPOR 2025, this poster explores how the Italian Medicines Agency uses real-world evidence in its innovativeness assessments and the impact of evidence quality on outcomes.

Assessing the Added Value of Fixed-Dose Combinations in Non-Communicable Diseases

Presented at ISPOR 2025, this study explores HTA decisions for fixed-dose combinations targeting non-communicable diseases, comparing outcomes across four major markets.

A Comparative Assessment of LLM Agreement for Clinical Data Extraction Tasks

Presented at ISPOR 2025, this study compares the clinical data extraction capabilities of large language models across HTA reports using a structured JSON schema.

Broadening the Evidence Base: Incorporating Environmental Considerations Into HTAs

Learn how environmental sustainability metrics like carbon footprinting, can be integrated into health technology assessments, as presented at ISPOR 2025.

Diffusion and Launch Sequencing of Cell and Gene Therapies across the USA, UK, Europe, Canada and Australia

Discover how cell and gene therapies are progressing from FDA approval to market access across the USA, UK, Europe, Canada, and Australia, as presented at ISPOR 2025.

May 19, 2025

Read article

